Capital Fund Management S.A. purchased a new position in Bruker Corp. (NASDAQ:BRKR) during the second quarter, according to its most recent filing with the SEC. The firm purchased 460,451 shares of the company’s stock, valued at approximately $10,471,000.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Thompson Rubinstein Investment Management Inc. OR increased its position in shares of Bruker Corp. by 0.8% in the second quarter. Thompson Rubinstein Investment Management Inc. OR now owns 172,300 shares of the company’s stock worth $3,918,000 after buying an additional 1,370 shares during the period. Legal & General Group Plc increased its position in shares of Bruker Corp. by 26.8% in the first quarter. Legal & General Group Plc now owns 8,125 shares of the company’s stock worth $228,000 after buying an additional 1,719 shares during the period. Aperio Group LLC increased its position in shares of Bruker Corp. by 15.9% in the first quarter. Aperio Group LLC now owns 22,079 shares of the company’s stock worth $618,000 after buying an additional 3,024 shares during the period. Bayesian Capital Management LP increased its position in shares of Bruker Corp. by 23.5% in the first quarter. Bayesian Capital Management LP now owns 18,900 shares of the company’s stock worth $529,000 after buying an additional 3,600 shares during the period. Finally, Shell Asset Management Co. increased its position in shares of Bruker Corp. by 9.5% in the second quarter. Shell Asset Management Co. now owns 45,407 shares of the company’s stock worth $1,033,000 after buying an additional 3,951 shares during the period. Hedge funds and other institutional investors own 69.92% of the company’s stock.
Shares of Bruker Corp. (NASDAQ:BRKR) traded up 0.35% during trading on Wednesday, hitting $22.71. 532,691 shares of the company were exchanged. Bruker Corp. has a 1-year low of $15.78 and a 1-year high of $29.85. The stock has a market capitalization of $3.66 billion, a PE ratio of 34.20 and a beta of 0.91. The company has a 50 day moving average of $22.23 and a 200-day moving average of $25.12.
Bruker Corp. (NASDAQ:BRKR) last posted its quarterly earnings results on Tuesday, August 2nd. The company reported $0.20 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.20. Bruker Corp. had a return on equity of 22.66% and a net margin of 6.86%. The company had revenue of $371.70 million for the quarter, compared to analysts’ expectations of $409.57 million. During the same period in the previous year, the firm earned $0.19 EPS. The firm’s revenue was down 6.1% compared to the same quarter last year. On average, analysts forecast that Bruker Corp. will post $1.00 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Friday, September 23rd. Investors of record on Tuesday, September 6th were issued a $0.04 dividend. The ex-dividend date of this dividend was Thursday, September 1st. This represents a $0.16 dividend on an annualized basis and a yield of 0.70%. Bruker Corp.’s dividend payout ratio is presently 24.24%.
A number of brokerages have recently issued reports on BRKR. Wells Fargo & Co. lowered shares of Bruker Corp. from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 3rd. Janney Montgomery Scott upgraded shares of Bruker Corp. from a “neutral” rating to a “buy” rating and set a $28.00 price objective for the company in a research note on Wednesday, August 3rd. BTIG Research reiterated a “neutral” rating on shares of Bruker Corp. in a research note on Friday, July 22nd. Zacks Investment Research upgraded shares of Bruker Corp. from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Wednesday, June 29th. Finally, Mizuho lowered their price objective on shares of Bruker Corp. from $28.00 to $23.00 and set a “neutral” rating for the company in a research note on Wednesday, August 3rd. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $25.80.
In other news, CEO Frank H. Laukien acquired 4,500 shares of Bruker Corp. stock in a transaction on Friday, August 5th. The shares were acquired at an average price of $22.17 per share, with a total value of $99,765.00. Following the purchase, the chief executive officer now directly owns 37,658,733 shares in the company, valued at approximately $834,894,110.61. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Richard A. Packer acquired 10,000 shares of Bruker Corp. stock in a transaction on Wednesday, August 10th. The stock was purchased at an average cost of $21.97 per share, for a total transaction of $219,700.00. Following the purchase, the director now owns 22,500 shares in the company, valued at $494,325. The disclosure for this purchase can be found here. 35.80% of the stock is owned by corporate insiders.
Bruker Corp. Company Profile
Bruker Corporation is a designer and manufacturer of scientific instruments, and analytical and diagnostic solutions. The Company’s operating segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corp. (NASDAQ:BRKR).
Receive News & Ratings for Bruker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corp. and related companies with MarketBeat.com's FREE daily email newsletter.